	Application No.	Applicant(s)
Notice of Allowability	10/665,184	BEN-SASSON ET AL.
	Examiner	Art Unit
	Robert B. Mondesi	1653
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. X This communication is responsive to <u>Amendment filed February 23, 2006</u> .		
2. The allowed claim(s) is/are <u>1-11,15,25,28-30,39-47,50-51,77-79,90,97,99,101 and 103-108.</u>		
3.		
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO-1449 or PTO/SB/C Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary Paper No./Mail Dat 08), 7. ☒ Examiner's Amendr	te

Application/Control Number: 10/665,184

Art Unit: 1653

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Christina Stock on April 6, 2006.

The application has been amended as follows:

Claim 1 (Currently amended) A penetration composition for non-invasive translocation of at least one effector across a biological barrier, said composition comprising:

- (a) a therapeutically effective amount of said effector;
- (b) a counter ion to the effector; and
- (c) a penetrating peptide consisting of the amino acid sequence of SEQ ID NO:24, wherein said penetrating peptide is hydrophobized.

Claim 102 (Cancelled)

Claim 103 (Currently amended) The penetration composition of claim <u>1</u><del>102</del>, wherein the penetrating peptide is further modified via one or more peptidic bonds, thereby protecting the peptide from gastrointestinal proteolysis.

Claim 104 (Currently amended) The penetration composition of claim <u>1</u><del>102</del>, wherein the penetrating peptide further comprises lysine residues interspaced by

Application/Control Number: 10/665,184 Page 3

Art Unit: 1653

glycine, alanine, or serine residues added at the C-terminus of said penetrating peptide, and wherein the free amino groups of said lysine residues are acylated.

## Conclusion

Claims 1-11, 15, 25, 28-30, 39-47, 50-51, 77-79, 90, 97, 99, 101 and 103-108 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert B. Mondesi whose telephone number is 571-272-0956. The examiner can normally be reached on 9am-5pm, Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Robert B. Mondesi

Robert B. Monder.

4-13-06

SUPERVISORY PATENT EXAMINER